CPL’36 Phase II clinical results to be presented at APA Annual Meeting
14 May 2025 | News
We’re excited to share that we’ll be presenting at the American Psychiatric Association (APA) Annual Meeting 2025, taking place May 17–21 in Los Angeles, California. Our team will showcase the Phase 2 clinical trial results of CPL’36, an innovative PDE10A inhibitor, in the treatment of acute exacerbations of schizophrenia. 📌 Poster session: May 18, 1:30–3:00Read more »
Welcome to Celon Pharma S.A.
Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.
News
- CPL’36 Phase II clinical results to be presented at APA Annual MeetingWe’re excited to share that we’ll be presenting at the American Psychiatric Association (APA) Annual Meeting 2025, taking place May 17–21 in Los Angeles, California. Our team will showcase theRead more »
- Current report 4/2025 – Phase II top – line results for CPL’ 36, a PDE10a inhibitor in the treatment of Dyskinesia in Parkinson’s diseaseLegal basis Art. 17 section 1 MAR - confidential information. Report content: In reference to current report 17/2024 regarding positive results of the Phase II clinical trial on a drugRead more »
- Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Oral Antipsychotic
